Last reviewed · How we verify

Herceptin IV [trastuzumab]

Hoffmann-La Roche · Phase 3 active Small molecule

Herceptin IV [trastuzumab] is a HER2-targeted monoclonal antibody Small molecule drug developed by Hoffmann-La Roche. It is currently in Phase 3 development for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings), HER2-positive metastatic gastric cancer.

Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.

Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death. Used for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings), HER2-positive metastatic gastric cancer.

At a glance

Generic nameHerceptin IV [trastuzumab]
SponsorHoffmann-La Roche
Drug classHER2-targeted monoclonal antibody
TargetHER2 (human epidermal growth factor receptor 2)
ModalitySmall molecule
Therapeutic areaOncology
PhasePhase 3

Mechanism of action

Herceptin targets human epidermal growth factor receptor 2 (HER2), a protein overexpressed in certain cancers. By binding to HER2, the drug prevents ligand-induced signaling and recruits immune cells to destroy HER2-positive tumor cells through antibody-dependent cellular cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Approved indications

Common side effects

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about Herceptin IV [trastuzumab]

What is Herceptin IV [trastuzumab]?

Herceptin IV [trastuzumab] is a HER2-targeted monoclonal antibody drug developed by Hoffmann-La Roche, indicated for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings), HER2-positive metastatic gastric cancer.

How does Herceptin IV [trastuzumab] work?

Trastuzumab is a monoclonal antibody that binds to HER2 receptors on cancer cells, blocking growth signals and triggering immune-mediated cell death.

What is Herceptin IV [trastuzumab] used for?

Herceptin IV [trastuzumab] is indicated for HER2-positive metastatic breast cancer, HER2-positive early-stage breast cancer (adjuvant and neoadjuvant settings), HER2-positive metastatic gastric cancer.

Who makes Herceptin IV [trastuzumab]?

Herceptin IV [trastuzumab] is developed by Hoffmann-La Roche (see full Hoffmann-La Roche pipeline at /company/roche).

What drug class is Herceptin IV [trastuzumab] in?

Herceptin IV [trastuzumab] belongs to the HER2-targeted monoclonal antibody class. See all HER2-targeted monoclonal antibody drugs at /class/her2-targeted-monoclonal-antibody.

What development phase is Herceptin IV [trastuzumab] in?

Herceptin IV [trastuzumab] is in Phase 3.

What are the side effects of Herceptin IV [trastuzumab]?

Common side effects of Herceptin IV [trastuzumab] include Cardiotoxicity / left ventricular dysfunction, Infusion reactions, Fever, Chills, Nausea, Diarrhea.

What does Herceptin IV [trastuzumab] target?

Herceptin IV [trastuzumab] targets HER2 (human epidermal growth factor receptor 2) and is a HER2-targeted monoclonal antibody.

Related